News

Cell therapy bemdaneprocel gets FDA RMAT status

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson’s disease. RMAT designation is granted to therapies that have shown potential to treat serious or life-threatening…

LRRK2, other gene mutations shared by IBD, Parkinson’s: Study

Researchers at the Icahn School of Medicine at Mount Sinai have identified LRRK2 gene mutations as a common element in both inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, and Parkinson’s disease. The study also identified genes involved in inflammation…